Department of Dermatology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Dermatol Ther. 2012 Mar-Apr;25(2):112-34. doi: 10.1111/j.1529-8019.2012.01491.x.
Dermatomyositis (DM) is traditionally classified as an idiopathic inflammatory myopathy distinguished by muscle weakness and characteristic cutaneous findings. Patients presenting with the skin manifestations in the absence of clinical evidence of muscle weakness are categorized as clinically amyopathic DM. The symptoms associated with the cutaneous findings can be particularly debilitating, and a discordant response to therapy exists between muscle and skin disease. Various therapeutic agents and treatment approaches have been described, both for the cutaneous and extracutaneous manifestations; however, a paucity of controlled studies in this disease leads to limitations in interpreting the available data. In this review, emphasis is placed specifically on summarizing the current literature regarding management of cutaneous DM. In addition, an algorithmic approach to treatment of skin disease is presented.
皮肌炎（DM）传统上被归类为特发性炎症性肌病，其特征为肌肉无力和特征性皮肤表现。以皮肤表现为特征但无肌肉无力临床证据的患者被归类为临床无肌病性皮肌炎。与皮肤表现相关的症状可能特别使人虚弱，肌肉和皮肤疾病的治疗反应存在差异。已经描述了各种治疗剂和治疗方法，包括皮肤和皮肤外表现；然而，由于该疾病缺乏对照研究，因此在解释现有数据方面存在局限性。在这篇综述中，特别强调总结有关皮肌炎皮肤管理的当前文献。此外，还提出了一种治疗皮肤疾病的算法方法。
